Scarica l'app Stockscreener
6.34
3.50%
-0.23
Precedente Chiudi:
$6.57
Aprire:
$6.52
Volume 24 ore:
2.85M
Relative Volume:
0.97
Capitalizzazione di mercato:
$1.82B
Reddito:
$7.47M
Utile/perdita netta:
$-129.88M
Rapporto P/E:
-16.00
EPS:
-0.3962
Flusso di cassa netto:
$-115.33M
1 W Prestazione:
-2.91%
1M Prestazione:
+17.41%
6M Prestazione:
+27.31%
1 anno Prestazione:
+148.63%
Intervallo 1D:
$5.99
$6.54
Intervallo di 1 settimana:
$5.99
$6.75
Portata 52W:
$2.34
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.34 | 1.82B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies president sells $1.25m in stock By Investing.com - Investing.com Australia
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA) - GuruFocus
Taysha Gene Therapies president sells $1.25m in stock - Investing.com
Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
Form 144 Taysha Gene Therapies For: 10 July By Investing.com - Investing.com Nigeria
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative? - simplywall.st
TSHA Q1 2026 Earnings: EPS Miss of -$0.12 vs. -$0.0996 Estimate; Stock Declines MarginallyManagement Guidance Update - dars.gov.et
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com India
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue - Sahm
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $12 to $15 - Moomoo
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Needham -- Price Target Holds at $12.00 - GuruFocus
Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
TSHA Maintained by Baird -- Price Target Raised to $15.00 - GuruFocus
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA - TradingView
Enterprise value to EBIT forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA - TradingView
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside - TradingView
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell 3000E Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS: TSHA) dropped from Russell Microcap Index - marketscreener.com
Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA) - Sahm
Taysha Gene Therapies launches $200M public offering; shares down - MSN
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha presents TSHA-102 data at 2026 IRSF Rett Syndrome meeting - scanx.trade
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M - MSN
Form 424B5 Taysha Gene Therapies Inc For: 25 June By Investing.com - Investing.com Nigeria
Taysha Gene Therapies to present Rett syndrome data at conference By Investing.com - Investing.com Nigeria
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - Investing News Network
Taysha Gene Therapies to present Rett syndrome data at conference - Investing.com
Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants - Stock Titan
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting - Traders Union
Taysha Gene Therapies (TSHA) priced 32.5M-share offering; $187M net proceeds - Stock Titan
Taysha Gene Therapies Announces Multiple Presentations - GlobeNewswire
Taysha Gene Therapies Down Over 11%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Taysha Gene Therapies (TSHA) Shares Fall 9.2% Following $200M Pu - GuruFocus
Taysha Gene Therapies, Inc. Actuals & Estimates (NASDAQ:TSHA) - TradingView
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session - Benzinga
Taysha Gene Therapies stock tumbles on public offering pricing By Investing.com - Investing.com Australia
Taysha Gene Therapies prices $200M public offering of common stock - scanx.trade
TSHA Secures New Offering at Discounted Price - GuruFocus
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):